Dublin, Jan. 08, 2018 (GLOBE NEWSWIRE) -- The "Drug Discovery Informatics Market by Function, Solution and End User - Global Forecast to 2022" report has been added to Research and Markets' offering.

The global drug discovery informatics market is expected to reach USD 2.84 Billion in 2022 from USD 1.67 Billion in 2017 at a CAGR of 11.2%.

The pharmaceutical industry deals with a huge amount of data in the process of drug discovery. Moreover, it takes approximately 10 years to bring a drug to the market from the start of the discovery process and drug discovery alone accounts for approximately 4 years of that time frame. The complete process of drug development and commercialization can cost as much as USD 1 to 2 billion. With such huge investments at stake, drug discovery informatics can help target the right compound and avoid negative outcomes. Rising R&D expenditure across the globe, increasing focus on drug delivery, and the need to control drug discovery and development costs are the factors driving the growth of this market.

In this report, the market has been categorized based on function, solution, end user, and region. Based on function, the drug discovery informatics market is divided into sequencing and target data analysis, docking, molecular modeling, libraries & database preparation, and other functions. In 2017, the sequencing and target data analysis segment is expected to account for the largest share of the market. Factors such as the expansive application of informatics solutions in targeted analysis and the large amount of data generated during the drug discovery process are driving the growth of this segment.

On the basis of solution, the market is classified into software and services. In 2017, the software segment is expected to account for the largest share of the global drug discovery informatics market. The largest share of this segment is attributed to the fast and efficient management of data generated throughout the drug discovery process using discovery informatics software solutions.

In 2017, in terms of value, North America is expected to account for the largest share of the global drug discovery informatics market. Asia Pacific is expected to register the highest growth rate from 2017 to 2022. This can be attributed to the fastest-growing APAC pharmaceutical market in the world, the availability of many qualified researchers, and the low cost of human resources and manufacturing.

The key players in the drug discovery informatics market are IBM (US), Infosys (India), Schrdinger (US), PerkinElmer (US), and Thermo Fisher Scientific (US).

Market Dynamics

Drivers

  • Rising R&D Expenditure
  • Increasing Focus On Drug Discovery
  • Need To Control Drug Discovery And Development Costs

Restraint

  • High Pricing And Setup Cost Of Informatics Software

Opportunities

  • Patent Expiry
  • Growing Biotechnology Industry

Challenge

  • Scarcity Of Skilled Professionals

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Drug Discovery Informatics Market, By Function

7 Drug Discovery Informatics Market, By Solution

8 Drug Discovery Informatics Market, By End User

9 Drug Discovery Informatics Market, By Region

10 Competitive Landscape

11 Company Profiles

  • Jubilant Life Sciences
  • IBM
  • Infosys
  • Thermo Fisher Scientific
  • Perkinelmer
  • Schrdinger
  • Dassault Systmes
  • Charles River Laboratories
  • Selvita
  • Certara
  • Gvk Biosciences
  • Collaborative Drug Discovery
  • Openeye Scientific Software
  • IO Informatics
  • Novo Informatics

For more information about this report visit https://www.researchandmarkets.com/research/7473wp/global_drug?w=12




CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Drug Discovery

Primary Logo